AVEO PHARMACEUTICALS, INC.

Fotivda-Opdivo Combination Shows Comparable Quality of Life Outcomes to Fotivda Alone in Advanced Kidney Cancer

3 months ago

• Phase 3 TiNivo-2 study demonstrates that combining Fotivda (tivozanib) with Opdivo (nivolumab) maintains similar patient-reported outcomes compared to Fotivda monotherapy in advanced renal cell carcinoma patients. • Approximately 75% of patients in both treatment arms reported improved or stable kidney cancer symptoms, with consistent quality of life scores maintained throughout the study period. • Safety profile analysis reveals lower rates of certain side effects in the combination therapy group, potentially due to lower dosing requirements, while maintaining established efficacy parameters.

FDA-Approved Fotivda Dose Shows Superior Efficacy in Renal Cell Carcinoma Treatment

3 months ago

• Analysis of three phase 3 trials demonstrates that the FDA-approved 1.34mg dose of Fotivda delivers superior antitumor activity compared to reduced 0.89mg dose in renal cell carcinoma patients. • Higher Fotivda exposure correlates with improved progression-free survival, with patients in the highest exposure quartile achieving 9.7 months median PFS versus 5.6 months in the lowest quartile. • Study reveals comparable hypertension risk between doses, while combination therapy with Opdivo at lower Fotivda dose showed no additional benefits over standard monotherapy.

Hepatocellular Carcinoma: Over 90 Companies Pursue Novel Therapies

8 months ago

• Over 90 pharmaceutical and biotech companies are actively developing more than 95 pipeline drugs for hepatocellular carcinoma (HCC). • Key companies like Can-Fite BioPharma are advancing HCC drug candidates, with some therapies in Phase III clinical trials. • Emerging therapies such as Namodenoson, SRF388, and Porustobart are expected to significantly impact the HCC market in the coming years. • The pipeline includes diverse routes of administration and molecule types, offering varied treatment options for HCC.

Robust Clinical Trial Pipeline Fuels Hope for Renal and Breast Cancer Advances

8 months ago

• The renal cancer clinical trial pipeline is robust, with over 70 companies developing more than 75 therapies, including novel immunotherapies and targeted agents. • Breast cancer research is also thriving, with over 100 companies exploring 120+ new drugs, such as antibody-drug conjugates and PARP inhibitors, in clinical trials. • Recent FDA actions, including Fast Track and Breakthrough Therapy designations, highlight the potential of emerging therapies for both renal and breast cancer. • Advances in diagnostics, such as PET imaging agents for clear cell renal cell carcinoma, are also contributing to improved management of these diseases.

Tivozanib Monotherapy Shows Superiority Over Tivozanib Plus Nivolumab in Metastatic RCC After ICI Progression

8 months ago

• The phase 3 TiNivo-2 trial revealed that tivozanib monotherapy demonstrated superior progression-free survival (PFS) compared to the combination of tivozanib and nivolumab in metastatic renal cell carcinoma (RCC). • Median PFS was 7.4 months with tivozanib alone versus 5.7 months with the combination, indicating that immune checkpoint inhibitor (ICI) rechallenge may not be beneficial in this setting. • The study suggests that tivozanib monotherapy at 1.34 mg can be considered a second-line treatment option for patients with RCC who have progressed after prior ICI therapy. • The reduced dose of tivozanib in the combination arm (0.89 mg) may have impacted the efficacy, highlighting the importance of optimal dosing in VEGFR TKI therapy.